Researchers found that a new fertility treatment called FemaSeed is now available in OB/GYN offices, allowing women to receive care more conveniently and affordably. This integrated approach combines sperm preparation with intratubal insemination (ITI) in one office visit. It aims to address the significant gap in fertility treatment access, as many women struggle to get help despite the increasing rates of infertility.

This development is particularly relevant for the approximately 10 million women in the U.S. facing infertility issues. By enabling earlier intervention within the familiar setting of their primary care provider, women can potentially improve their chances of conception without the high costs and complexities associated with traditional in vitro fertilization (IVF). Clinical trials have shown that FemaSeed has more than double the pregnancy rate compared to traditional intrauterine insemination (IUI), making it a promising option for those seeking to start or expand their families.

Currently, FemaSeed is in the early stages of commercial use, having recently received FDA clearance and validation in infertility centers. While the initial results are encouraging, it’s important to note that this treatment is still being evaluated in broader clinical settings. The evidence is strong but not yet definitive, so women interested in this option should consult their healthcare providers to discuss their individual circumstances and the best path forward.

For those exploring fertility options, consider discussing FemaSeed with your OB/GYN. This treatment may provide a more accessible and streamlined approach to achieving pregnancy, especially if you have faced challenges with traditional methods.

Source: globenewswire.com